Capital Fund Management (CFM)
APLS

Capital Fund Management (CFM)’s Apellis Pharmaceuticals APLS Stock Holding History

Capital Fund Management (CFM)’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,300
Closed -$324K – 2348
2025
Q3 		$324K Sell
14,300
-200
-1% -$4.66K ﹤0.01% 2373
2025
Q2 		$251K Buy
+14,500
New +$268K ﹤0.01% 2295
2024
Q1 		– Sell
-50,400
Closed -$3.02M – 1964
2023
Q4 		$3.02M Sell
50,400
-7,300
-13% -$370K 0.01% 1330
2023
Q3 		$2.19M Buy
57,700
+47,600
+471% +$2.09M 0.01% 1314
2023
Q2 		$920K Buy
+10,100
New +$871K ﹤0.01% 1421

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capital Fund Management (CFM)'s APLS Position: Q1 2026 in Review

Capital Fund Management (CFM) opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 68,112 shares worth $2.74M. The stake represents 0.01% of the portfolio and ranks #1203 among its holdings. This is a return to the name: Capital Fund Management (CFM) previously reported a position in APLS as recently as Q4 2024.

Capital Fund Management (CFM) first reported a position in APLS in Q1 2022 and has held it in 6 quarters since. The position peaked at $7.73M in Q2 2024. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Capital Fund Management (CFM) held 68,112 shares of Apellis Pharmaceuticals worth $2.74M as of Q1 2026.
  • Apellis Pharmaceuticals was a new Capital Fund Management (CFM) position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #1203 holding.
  • Capital Fund Management (CFM) first reported a position in Apellis Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
  • Capital Fund Management (CFM)'s Apellis Pharmaceuticals position peaked at $7.73M in Q2 2024.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.